Stockscreener 앱 받기
8.24
1.23%
0.10
시간 외 거래:
8.24
Sight Sciences Inc 주식(SGHT)의 최신 뉴스
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - TipRanks
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance - VisionMonday.com
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall - Investing.com Nigeria
Sight Sciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Sight Sciences : Reports Second Quarter 2026 Financial Results - marketscreener.com
Sight Sciences wins FDA clearance for Omni Surgical System - MassDevice
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com - Investing.com South Africa
Sight Sciences Q2 revenue rises 20%, beats estimates - TradingView
Aetna covers Sight Sciences glaucoma devices for commercial plans - Investing.com
Sight Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Sight Sciences, Inc. Q2 2026: Revenue $23.39M, EPS $(0.08) — 10-Q Summary - TradingView
Sight Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth - Stock Titan
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems - The Manila Times
BRIEF-Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million - TradingView
Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms - Bitget
FDA Clears Sight Sciences’ OMNI Ultra Surgical System - Medical Product Outsourcing
Sight Sciences lifts guidance after strong Q2 results - TipRanks
FDA clears Sight Sciences’ OMNI Ultra glaucoma device - Investing.com
FDA clears Sight Sciences’ OMNI Ultra glaucoma device By Investing.com - Investing.com India
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System - The Manila Times
Sight Sciences Announces FDA 510(k) Clearance of OMNI Ultra Surgical System for Primary Open-Angle Glaucoma - Quiver Quantitative
Sight Sciences' FDA-cleared glaucoma system leaves no implant behind - stocktitan.net
Sight Sciences wins FDA 510(k) clearance for OMNI Ultra glaucoma system - Bitget
Earnings To Watch: Sight Sciences Inc (SGHT) Q2 2026 -- GF Value Sees 9% Downside - Yahoo Finance
Sight Sciences, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $7 From $11, Maintains Buy Rating - Yahoo Finance
Sight Sciences Inc (SGHT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sight Sciences Market Sentiment - Benzinga España
Sight Sciences Inc (SGHT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sight Sciences Inc (SGHT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sight Sciences, Inc. $SGHT Position Lessened by Walleye Capital LLC - MarketBeat
TradingKey - TradingKey
2.43%
자본화:
|
볼륨(24시간):